Screener
Vor Biopharma VOR Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | $35,160 | $33,291 |
| Loss from operations | (35,160) | (33,291) |
| Other income (expense): | ||
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
| Total other (expense) income | (184,425) | 805 |
| Net loss | $(219,585) | $(32,486) |
| Net loss per share attributable to common stockholders, basic and diluted(1) | $(5.11) | $(5.21) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's interest income?
- Vor Biopharma (VOR) reported interest income of $3.94M in Q1 2026.
- How has Vor Biopharma's interest income changed year-over-year?
- Vor Biopharma's interest income increased by 388.8% year-over-year, from $805K to $3.94M.
- What is the long-term trend for Vor Biopharma's interest income?
- Over 4 years (2021 to 2025), Vor Biopharma's interest income has grown at a 165.0% compound annual growth rate (CAGR), from $119K to $5.87M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Vor Biopharma's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude